SWX:NOVNPharmaceuticals
Is Novartis (SWX:NOVN) Undervalued As EU Expands Approval For Its Gene Therapy?
Regulators in the United States and European Union have widened access to several gene therapies, with the European Commission approving Novartis (SWX:NOVN) product onasemnogene abeparvovec for a broader group of patients with 5q spinal muscular atrophy.
See our latest analysis for Novartis.
Against this backdrop, Novartis shares are trading at CHF123.26, with a 30 day share price return of 2.97% and year to date share price return of 13.60%. The 1 year total shareholder return of 36.07%...